中华神经外科疾病研究杂志
中華神經外科疾病研究雜誌
중화신경외과질병연구잡지
Chinese Journal of Neurosurgical Disease Research
2015年
4期
334-337
,共4页
赵莺%丁文秀%尹小祥%叶宏勋
趙鶯%丁文秀%尹小祥%葉宏勛
조앵%정문수%윤소상%협굉훈
胶质母细胞瘤%调强放疗%替莫唑胺%化疗
膠質母細胞瘤%調彊放療%替莫唑胺%化療
효질모세포류%조강방료%체막서알%화료
Glioblastoma%Intensity-modulated radiation therapy%Temozolomide%Chemotherapy
目的:分析比较替莫唑胺化疗联合调强放疗和单纯调强放疗治疗脑胶质母细胞瘤术后残留患者的疗效和安全性。方法胶质母细胞瘤术后局部有残留患者共36例,随机分为观察组和对照组,各18例。观察组在调强放疗时同步口服替莫唑胺化疗,对照组行单纯调强放疗,两组放疗方法相同。治疗期间观察治疗副作用,在所有患者治疗结束后定期随访,影像学动态观察患者肿瘤体积的变化及Karnofsky评分评价神经功能状态。结果观察组肿瘤体积的缩小和神经功能评分的改善均优于对照组(P<0.05)。两组生存率比较有统计学意义(P<0.05)。两组不良反应有恶心、呕吐、头痛及骨髓抑制等,程度均较轻,无重要脏器损害,未影响治疗。结论替莫唑胺化疗联合调强放疗疗效优于单纯调强放疗,且不良反应可耐受。
目的:分析比較替莫唑胺化療聯閤調彊放療和單純調彊放療治療腦膠質母細胞瘤術後殘留患者的療效和安全性。方法膠質母細胞瘤術後跼部有殘留患者共36例,隨機分為觀察組和對照組,各18例。觀察組在調彊放療時同步口服替莫唑胺化療,對照組行單純調彊放療,兩組放療方法相同。治療期間觀察治療副作用,在所有患者治療結束後定期隨訪,影像學動態觀察患者腫瘤體積的變化及Karnofsky評分評價神經功能狀態。結果觀察組腫瘤體積的縮小和神經功能評分的改善均優于對照組(P<0.05)。兩組生存率比較有統計學意義(P<0.05)。兩組不良反應有噁心、嘔吐、頭痛及骨髓抑製等,程度均較輕,無重要髒器損害,未影響治療。結論替莫唑胺化療聯閤調彊放療療效優于單純調彊放療,且不良反應可耐受。
목적:분석비교체막서알화료연합조강방료화단순조강방료치료뇌효질모세포류술후잔류환자적료효화안전성。방법효질모세포류술후국부유잔류환자공36례,수궤분위관찰조화대조조,각18례。관찰조재조강방료시동보구복체막서알화료,대조조행단순조강방료,량조방료방법상동。치료기간관찰치료부작용,재소유환자치료결속후정기수방,영상학동태관찰환자종류체적적변화급Karnofsky평분평개신경공능상태。결과관찰조종류체적적축소화신경공능평분적개선균우우대조조(P<0.05)。량조생존솔비교유통계학의의(P<0.05)。량조불량반응유악심、구토、두통급골수억제등,정도균교경,무중요장기손해,미영향치료。결론체막서알화료연합조강방료료효우우단순조강방료,차불량반응가내수。
Objective The efficacy and safety of Temozolomide plus intensity-modulated radiation therapy (IMRT) and IMRT alone in the treatment for post-operative local residual of glioblastoma.Methods A total of 36 patients with local residual of glioblastoma post-operatively were divided into observation group and control group randomly.In the observation group, intensity modulated radiation therapy ( IMRT ) was synchronized with temozolomide chemotherapy, while the control group with IMTR alone.Radiation method was the same in two groups. The side effects during tumor treatment were observed.All patients were followed up after treatment.The change of tumor size was observed and score of Karnofsky Performance status was used to evaluate the neurologic status.Results Both tumor volume reduction and the improvement of nerve function score in observation group were better than those of control group (P<0.05).There was significant difference in survival rate between two groups (P<0.05). Adverse reactions in two groups were slight, such as nausea, vomiting, headaches or bone marrow suppression, etc, and no important organ damage happened, which did no affect the treatment.Conclusion The curative effect of IMRT combined with temozolomide chemotherapy is better than IMRT alone, and the adverse reactions are tolerable.